BioSpace News Archive

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a phase 2, investigator-sponsored trial of cabozantinib (CABOMETYX®) in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Bristol Myers Squibb announced results from the primary analysis of PILOT, a multicenter, Phase 2 study evaluating Breyanzi in adults with refractory or relapsed large B-cell lymphoma after first-line therapy who were not deemed candidates for high-dose chemotherapy and hematopoietic stem cell transplant.

Genentech, a member of the Roche Group, announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology Annual Meeting from June 3-7 and the European Hematology Association 2022 Congress from June 9-12.

Regulatory News: Ipsen announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor, Cabometyx®, across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting to be held on 3-7 June.

Veracyte, Inc. (Nasdaq: VCYT) announced today new data from a clinical research study demonstrating the ability of its Immunoscore Immune Checkpoint (IC) assay to predict which patients with metastatic non-small cell lung cancer (NSCLC) may benefit from immune checkpoint inhibitors (ICIs).

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced the publication of an abstract at the American Society of Clinical Oncology Annual Meeting.

SpringWorks Therapeutics, Inc. announced initial clinical data from the Phase 1/2 study evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with BLENREP, GSK plc’s antibody drug conjugate targeting B-cell maturation agent, in patients with relapsed or refractory multiple myeloma.

Aadi Bioscience, Inc. announced presentation of a poster entitled, “nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program” at the 2022 American Society of Clinical Oncology Annual Meeting, being held online and in person from June 3-7 in Chicago, IL.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), today announced that complete HB-200 Phase 1 results (NCT04180215) for single-vector HB-201 and alternating 2-vector HB-202/HB-201 in patients with advanced Human Papillomavirus 16-positive (HPV16+) cancers, including the recommended Phase 2 dose for HB-202/HB-201, will be shared in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Iovance Biotherapeutics, Inc. reported clinical results from its C-144-01 clinical study in patients with advanced melanoma who progressed on prior anti-PD-1/L1 therapy, and if BRAF mutation positive, also on prior BRAF or BRAF/MEK inhibitor therapy.